Calciphylaxis Market Size

Calciphylaxis Market Growth Projections and Opportunities

The market for calciphylaxis is rapidly expanding, mainly due to the increasing number of people with end-stage renal disease (ESRD). This condition affects a significant number of individuals, with more than 650,000 patients in the United States and around 2 million worldwide facing ESRD each year, according to the Regents of the University of California. The rise in ESRD cases is a key factor driving the growth of the calciphylaxis market. Additionally, the market is influenced by the growing population of dialysis patients. The U.S. Renal Data System Annual Data Report noted that in 2016, over 660,000 Americans were receiving treatment for end-stage renal disease, with 468,000 of them undergoing dialysis.
In terms of diagnosing calciphylaxis, the market is divided into three segments: deep skin biopsies, blood tests, and imaging. Deep skin biopsies held the largest market share in 2016, primarily because they are effective in confirming the diagnosis of calciphylaxis at an early stage. Blood tests constitute the second-largest market segment, with a projected compound annual growth rate (CAGR) of 10.99% from 2017 to 2023, according to the U.S. Renal Data System.

The treatment segment of the calciphylaxis market is further divided into various categories, including intensive wound care, medication, therapy, clot-dissolving, and others. Intensive wound care dominated the market in 2016, accounting for 32% of the total market share. This growth is attributed to the increasing prevalence of calciphylaxis and the widespread use of aggressive wound care to address issues such as skin ulceration and necrotic skin lesions. The global calciphylaxis market for treatment is expected to reach USD 3,722.6 million by 2023, up from USD 1,646.0 million in 2016, projecting a CAGR of 10.70% during the forecast period from 2017 to 2023.

In summary, the calciphylaxis market is witnessing substantial growth, driven by the rising incidence of end-stage renal disease and the increasing number of dialysis patients. The diagnostic methods, particularly deep skin biopsies, play a crucial role in early detection, while intensive wound care emerges as a significant treatment approach. With a projected increase in market size and continuous advancements, the calciphylaxis market is poised for further expansion in the coming years.